CUV.AX
Clinuvel Pharmaceuticals Limited
ASXAUDEQUITY
Healthcare
DELAYED
Last price
10.42
▼ 0.47 (4.32%)
MARKET · —
Price
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
10.76
Prev close
10.89
Day high
10.99
Day low
10.30
Volume
109.46K
Market cap
$525.46M
P/E (TTM)
16.28
52W range
8.35 – 14.00
Trailing performance
Returnvs SPY
1W
+9.11%
+10.5%
1M
+4.72%
+1.0%
3M
+17.47%
+14.4%
6M
-7.95%
-19.0%
YTD
-16.37%
-28.7%
1Y
-21.18%
-41.2%
3Y
-50.71%
-124.9%
5Y
-69.79%
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CUV.AX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
8.32M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 12, 25 | Wright (Dennis J) Divisional Officer |
— | 3.50K | — | Direct |
| Jun 30, 25 | Vaughan (Peter) Chief Financial Officer |
— | 3.50K | — | Direct |
| Oct 16, 24 | Shanahan (Brenda Mary) Former |
— | 80.00K | — | Direct |
| Oct 3, 24 | Agersborg (Karen) Director (Non-Executive) |
OTHER | 8.33K | $87.88K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Agersborg (Karen) |
Director (Non-Executive) | 13.83K | Other |
Shanahan (Brenda Mary) |
Former | 116.58K | Other |
Vaughan (Peter) |
Chief Financial Officer | 3.50K | Other |
Wright (Dennis J) |
Divisional Officer | 192.31K | Other |
Fundamentals
Market cap$525.46M
Enterprise value$290.01M
Revenue (TTM)$96.30M
Gross profit$86.32M
EBITDA$43.68M
Net income$32.54M
EPS (TTM)$0.64
Free cash flow$32.20M
Total cash$233.00M
Total debt$323.84K
Book value / share$4.96
Shares outstanding50.43M
Float43.65M
Short % of float—
Dividend yield0.48%
Beta (5Y)0.57
Valuation & profitability ratios
Trailing P/E16.28
Forward P/E13.78
PEG ratio0.65
Price / sales—
Price / book2.10
EV / revenue3.01
EV / EBITDA6.64
Gross margin89.63%
Operating margin36.59%
Profit margin33.79%
Return on equity13.96%
Return on assets10.62%
Debt / equity0.13
Current ratio14.64
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $95.02M | $88.18M | $78.32M | $65.72M | +7.8% |
| Operating revenue | $95.02M | $88.18M | $78.32M | $65.72M | +7.8% |
| Cost of revenue | $15.88M | $10.08M | $8.79M | $10.48M | +57.5% |
| Gross profit | $79.14M | $78.10M | $69.53M | $55.24M | +1.3% |
| Selling, general & admin | $26.85M | $25.03M | $22.57M | $17.71M | +7.3% |
| Total operating expense | $33.40M | $30.09M | $25.43M | $19.91M | +11.0% |
| Operating income | $45.73M | $48.01M | $44.10M | $35.33M | -4.7% |
| Net interest income | $4.97M | $2.87M | $713.14K | -$1.83M | +73.1% |
| Pre-tax income | $51.55M | $50.68M | $45.58M | $34.32M | +1.7% |
| Tax provision | $15.38M | $15.04M | $14.97M | $13.44M | +2.2% |
| Net income | $36.17M | $35.64M | $30.60M | $20.88M | +1.5% |
| Net income to common | $36.17M | $35.64M | $30.60M | $20.88M | +1.5% |
| Basic EPS | 0.72 | 0.72 | 0.62 | 0.42 | +1.0% |
| Diluted EPS | 0.72 | 0.70 | 0.59 | 0.40 | +2.9% |
| EBIT | $56.02M | $55.13M | $48.77M | $36.60M | +1.6% |
| EBITDA | $57.20M | $56.28M | $49.56M | $37.35M | +1.6% |
| Basic shares | 50.08M | 49.83M | 49.41M | 49.41M | +0.5% |
| Diluted shares | 50.38M | 51.05M | 51.78M | 51.81M | -1.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $224.11M | $183.87M | $156.81M | $121.51M | +21.9% |
| Cash & short-term investments | $224.11M | $183.87M | $156.81M | $121.51M | +21.9% |
| Accounts receivable | $24.32M | $25.16M | $20.81M | $15.90M | -3.4% |
| Inventory | $8.82M | $10.63M | $9.52M | $1.83M | -17.0% |
| Total current assets | $262.97M | $222.06M | $189.62M | $140.58M | +18.4% |
| Property, plant & equipment | $7.13M | $7.72M | $2.85M | $2.70M | -7.7% |
| Goodwill & intangibles | $185.03K | $185.03K | $185.03K | $185.03K | 0.0% |
| Total assets | $271.75M | $231.12M | $193.71M | $143.95M | +17.6% |
| Total current liabilities | $27.21M | $25.21M | $25.49M | $13.73M | +7.9% |
| Total debt | $528.53K | $879.78K | $999.87K | $1.26M | -39.9% |
| Total liabilities | $30.94M | $28.11M | $29.08M | $18.39M | +10.1% |
| Retained earnings | $63.63M | $29.96M | -$9.77M | -$38.40M | +112.4% |
| Shareholder equity | $240.81M | $203.01M | $164.63M | $125.56M | +18.6% |
| Working capital | $235.76M | $196.85M | $164.12M | $126.85M | +19.8% |
| Net tangible assets | $240.62M | $202.83M | $164.45M | $125.37M | +18.6% |
| Shares issued | 50.12M | 50.08M | 49.41M | 49.41M | +0.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Capital expenditure | -$298.57K | -$5.58M | -$1.03M | -$434.44K | +94.6% |
| Investing cash flow | -$47.72M | -$29.03M | -$1.03M | -$434.44K | -64.3% |
| Share buybacks | -$440.91K | -$4.91M | — | — | +91.0% |
| Dividends paid | -$2.50M | -$2.47M | -$1.98M | -$1.24M | -1.4% |
| Financing cash flow | -$2.94M | -$3.57M | -$2.24M | -$1.50M | +17.7% |
| Free cash flow | $40.80M | $31.48M | $35.88M | $39.44M | +29.6% |
| End cash position | $28.02M | $35.20M | $156.81M | $121.51M | -20.4% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-06-30 | YoY |
|---|---|---|
| Cash & equivalents | $224.11M | |
| Cash & short-term investments | $224.11M | |
| Accounts receivable | $24.32M | |
| Inventory | $8.82M | |
| Total current assets | $262.97M | |
| Property, plant & equipment | $7.13M | |
| Goodwill & intangibles | $185.03K | |
| Total assets | $271.75M | |
| Total current liabilities | $27.21M | |
| Total debt | $528.53K | |
| Total liabilities | $30.94M | |
| Retained earnings | $63.63M | |
| Shareholder equity | $240.81M | |
| Working capital | $235.76M | |
| Net tangible assets | $240.62M | |
| Shares issued | 50.12M |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | 0.71 | 7 | $99.21M | +4.4% |
| Next year | 0.76 | 7 | $104.60M | +5.4% |
Analyst targets & ownership
Mean target$23.04
High target$40.80
Low target$13.00
Implied upside121.13%
Analyst count7
ConsensusSTRONG BUY
Strong buy / Buy1 / 7
Hold0
Sell / Strong sell0 / 0
Held by insiders16.59%
Held by institutions12.94%
Institutions holding23
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
9.98
+4.38% from price
SMA 20
9.69
+7.56% from price
SMA 50
9.93
+4.96% from price
SMA 100
9.53
+9.30% from price
SMA 200
10.47
-0.44% from price
EMA 12
10.04
+3.76% from price
EMA 26
9.88
+5.46% from price
EMA 50
9.81
+6.23% from price
RSI (14)
60.0
Neutral
MACD (12,26,9)
0.16
Hist 0.14
ATR (14)
0.42
4.04% of price
Realised vol 30D
36.2%
Annualised
Bollinger upper
10.64
20, 2σ
Bollinger lower
8.73
20, 2σ
50 / 200 cross
Death
9.93 vs 10.47
Trend bias
Below 200
-0.44%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.07
Less volatile than market
Correlation to SPY
-0.02
Largely independent
Realised vol 30D
36.2%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-36.4%
Peak to trough
Max drawdown 5Y
-80.0%
Peak to trough
ATR 14
0.42
4.04% of price
Beta (reported)
0.57
5Y monthly, from filing
Dividends & splits
Forward rate$0.05 / yr
Forward yield0.48%
5-year avg yield0.30%
Payout ratio7.76%
Ex-dividend dateSep 4, 2025
Next pay date—
Last split1:10
Split dateNov 12, 2010
Headlines
Gundir Announces Gundir365(TM) Postage Promise, Locking In Direct Mail Postage Rates for a Full Year
ACCESS Newswire · 9m ago
Why Keysight Technologies Stock Sank This Week
Motley Fool · 15m ago
Sydney marathon unveils medal with wrong stadium
AFP · 18m ago
Atlassian (TEAM) Stock Looks Near Fair Value After Its 98% Run
Simply Wall St. · 22m ago
Is Vestas Wind Systems (CPSE:VWS) Fully Valued As Earnings Lifted Full Year Guidance?
Simply Wall St. · 22m ago
Clorox (CLX) Could Be 56% Below Fair Value As Valuation Views Split
Simply Wall St. · 22m ago
Red Cat Holdings (RCAT) Expands Blue Ops Integration, Is The Upside Already Priced In?
Simply Wall St. · 23m ago
Chiefs vs. Buccaneers highlights Preseason Week 2
NFL Highlights · 30m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.